MI: making therapeutic choices when the options are unclear.
Aged adults are particularly susceptible to cardiac disease, with a high incidence of myocardial infarction (MI) and MI-related mortality. How to treat them is not completely understood, because the major therapeutic trials for MI have studied predominantly younger adults. Moreover, these trials have tended to exclude women and patients with comorbidities, characteristics that are more typical of older cardiac patients. Therefore, whether these trials can be applied to our aged MI patients is unclear. This review analyzes data from earlier trials to better delineate their implications for the elderly MI patients that we frequently treat.
Forman
D E
DE
Department of Internal Medicine, Beth Israel Hospital, Boston.
Wei
J Y
JY
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D000375:Aging / Q000378:metabolism*; D015906:Angioplasty, Balloon, Coronary; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality / Q000628:therapy*; D012307:Risk Factors; D012737:Sex Factors
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D005343:Fibrinolytic Agents